China Approves Inhaled Covid Vaccine

The video discusses the development and challenges of inhaled COVID-19 vaccines, highlighting the benefits of mucosal immunization in preventing virus transmission. It compares the efficacy of inhaled vaccines to injectable ones and explores the development of mRNA vaccines. The video also touches on Cansino's market position and its diverse vaccine pipeline.

What is one of the main limitations of current COVID-19 vaccines?

• They have severe side effects.

• They require multiple doses.

• They cannot block transmission.

• They are too expensive.

What is the primary focus of mucosal immunization?

• To stimulate mucosal immune response.

• To enhance antibody production.

• To reduce vaccine costs.

• To increase vaccine shelf life.

What was a significant challenge in developing the inhaled COVID-19 vaccine?

• Reducing production costs.

• Increasing the vaccine's shelf life.

• Finding a suitable delivery method.

• Ensuring it works for all age groups.

How does the efficacy of the inhaled vaccine compare to the injectable version?

• It is not yet determined.

• It is about the same or better.

• It is significantly higher.

• It is significantly lower.

What additional immune response does the inhaled vaccine provide?

• Mucosal immune response.

• Longer-lasting immunity.

• Enhanced cell-mediated immunity.

• Increased antibody production.

What stage is the mRNA vaccine currently in?

• Pre-clinical testing.

• Phase 3 clinical trial.

• Phase 2 clinical trial.

• Phase 1 clinical trial.

What is one reason for the company's stock price decline?

• Investor skepticism.

• High production costs.

• Limited vaccine efficacy.

• Lack of government support.